title: A prospective trial on the effect of body mass index and sex on plasma octreotide levels in patients undergoing long-term octreotide LAR therapy.
abstract: OBJECTIVE
  Octreotide long acting repeatable (LAR) is commonly used to control the symptoms of patients with functional neuroendocrine tumors. Unfortunately, most patients escape control over time and require higher LAR doses or more frequent rescue therapy to remain asymptomatic. Previous work has shown that body weight and monthly LAR dose will significantly affect circulating plasma octreotide levels in patients undergoing therapy.
  
  
  METHODS
  To determine if other parameters change circulating plasma octreotide levels, we prospectively studied 82 patients undergoing long-term LAR therapy.
  
  
  RESULTS
  Multivariate analysis demonstrated that the plasma octreotide levels decrease by approximately 3.4% for each unit of body mass index (BMI) increase (P = 0.03), adjusting for sex and monthly LAR dose. Plasma octreotide levels for females were approximately 47.6% higher than those for males (P = 0.045), adjusting for BMI and monthly LAR dose. Initial and subsequent octreotide LAR doses should take into consideration sex and BMI. Males are estimated to require 14.1-mg (SD, 7.25) higher monthly LAR doses than females with the same BMI.
  
  
  CONCLUSIONS
  We have shown that plasma octreotide levels are affected by not only monthly LAR dose but also BMI and sex. We hope these observations will make choosing initial and subsequent octreotide LAR doses easier for physicians.
authors.affiliation: Sections of Surgical Endocrinology and Hepatobiliary Surgery, Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
authors.forename: Saju
authors.initials: S
authors.lastname: Joseph
authors.forename: Gang
authors.initials: G
authors.lastname: Li
authors.forename: Erika
authors.initials: E
authors.lastname: Lindholm
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhou
authors.forename: Vay Liang W
authors.initials: VL
authors.lastname: Go
authors.forename: Aaron I
authors.initials: AI
authors.lastname: Vinik
authors.forename: Thomas M
authors.initials: TM
authors.lastname: O'Dorisio
authors.forename: Gregg
authors.initials: G
authors.lastname: Mamikunian
authors.forename: Eugene A
authors.initials: EA
authors.lastname: Woltering
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D015992:Body Mass Index; D005260:Female; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D015282:Octreotide / Q000008:administration & dosage* / Q000097:blood*; D011446:Prospective Studies; D012737:Sex Factors
chemical_list: D018931:Antineoplastic Agents, Hormonal; D015282:Octreotide
references.citation: J Clin Oncol. 1999 Feb;17(2):600-6
references.pmid: 10080605
references.citation: Pancreas. 2005 Nov;31(4):392-400
references.pmid: 16258376
references.citation: Pancreas. 2008 Jul;37(1):94-100
references.pmid: 18580450
references.citation: Ann Oncol. 2004 Jun;15(6):966-73
references.pmid: 15151956
references.citation: Regul Pept. 1993 Apr 8;44(3):285-95
references.pmid: 8097891
references.citation: Dig Dis Sci. 1995 Jul;40(7):1464-73
references.pmid: 7628270